AU2017250448C1 - Heterocyclic compounds as RET kinase inhibitors - Google Patents

Heterocyclic compounds as RET kinase inhibitors Download PDF

Info

Publication number
AU2017250448C1
AU2017250448C1 AU2017250448A AU2017250448A AU2017250448C1 AU 2017250448 C1 AU2017250448 C1 AU 2017250448C1 AU 2017250448 A AU2017250448 A AU 2017250448A AU 2017250448 A AU2017250448 A AU 2017250448A AU 2017250448 C1 AU2017250448 C1 AU 2017250448C1
Authority
AU
Australia
Prior art keywords
amino
alkyl
pyrazolo
pyrimidin
indole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017250448A
Other languages
English (en)
Other versions
AU2017250448B2 (en
AU2017250448A1 (en
Inventor
Euan Alexander Fraser Fordyce
George Hynd
Allan Jordan
Rebecca NEWTON
Silvia PAOLETTA
Jonathan Mark Sutton
Bohdan Waszkowycz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Research Technology Ltd
Original Assignee
Cancer Research Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Technology Ltd filed Critical Cancer Research Technology Ltd
Publication of AU2017250448A1 publication Critical patent/AU2017250448A1/en
Publication of AU2017250448B2 publication Critical patent/AU2017250448B2/en
Priority to AU2020220079A priority Critical patent/AU2020220079B2/en
Application granted granted Critical
Publication of AU2017250448C1 publication Critical patent/AU2017250448C1/en
Priority to AU2022203916A priority patent/AU2022203916A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2017250448A 2016-04-15 2017-04-18 Heterocyclic compounds as RET kinase inhibitors Active AU2017250448C1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2020220079A AU2020220079B2 (en) 2016-04-15 2020-08-18 Heterocyclic compounds as RET kinase inhibitors
AU2022203916A AU2022203916A1 (en) 2016-04-15 2022-06-06 Heterocyclic compounds as RET kinase inhibitors

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB201606631 2016-04-15
GB1606631.8 2016-04-15
GB201619277 2016-11-14
GB1619277.5 2016-11-14
PCT/GB2017/051076 WO2017178844A1 (en) 2016-04-15 2017-04-18 Heterocyclic compounds as ret kinase inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020220079A Division AU2020220079B2 (en) 2016-04-15 2020-08-18 Heterocyclic compounds as RET kinase inhibitors

Publications (3)

Publication Number Publication Date
AU2017250448A1 AU2017250448A1 (en) 2018-11-01
AU2017250448B2 AU2017250448B2 (en) 2020-05-21
AU2017250448C1 true AU2017250448C1 (en) 2021-01-07

Family

ID=58633035

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2017250448A Active AU2017250448C1 (en) 2016-04-15 2017-04-18 Heterocyclic compounds as RET kinase inhibitors
AU2020220079A Active AU2020220079B2 (en) 2016-04-15 2020-08-18 Heterocyclic compounds as RET kinase inhibitors
AU2022203916A Abandoned AU2022203916A1 (en) 2016-04-15 2022-06-06 Heterocyclic compounds as RET kinase inhibitors

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2020220079A Active AU2020220079B2 (en) 2016-04-15 2020-08-18 Heterocyclic compounds as RET kinase inhibitors
AU2022203916A Abandoned AU2022203916A1 (en) 2016-04-15 2022-06-06 Heterocyclic compounds as RET kinase inhibitors

Country Status (24)

Country Link
US (4) US10954241B2 (OSRAM)
EP (2) EP3442980B1 (OSRAM)
JP (3) JP6943876B2 (OSRAM)
KR (3) KR102706837B1 (OSRAM)
CN (2) CN115650985B (OSRAM)
AU (3) AU2017250448C1 (OSRAM)
BR (2) BR112018071097B1 (OSRAM)
CA (1) CA3020778A1 (OSRAM)
CY (1) CY1124478T1 (OSRAM)
DK (1) DK3442980T3 (OSRAM)
ES (1) ES2886587T3 (OSRAM)
HR (1) HRP20211362T1 (OSRAM)
HU (1) HUE056135T2 (OSRAM)
IL (3) IL297192A (OSRAM)
LT (1) LT3442980T (OSRAM)
MX (2) MX387394B (OSRAM)
PL (1) PL3442980T3 (OSRAM)
PT (1) PT3442980T (OSRAM)
RS (1) RS62322B1 (OSRAM)
RU (1) RU2742115C2 (OSRAM)
SG (2) SG11201808878UA (OSRAM)
SI (1) SI3442980T1 (OSRAM)
SM (1) SMT202100538T1 (OSRAM)
WO (1) WO2017178844A1 (OSRAM)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105693720B (zh) 2010-05-20 2019-01-18 阵列生物制药公司 作为trk激酶抑制剂的大环化合物
EP3322706B1 (en) 2015-07-16 2020-11-11 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
TWI757256B (zh) 2015-11-02 2022-03-11 美商纜圖藥品公司 轉染過程重排之抑制劑
PT3442535T (pt) 2016-04-15 2022-09-05 Cancer Research Tech Ltd Compostos heterocíclicos como inibidores da ret quinase
RS62322B1 (sr) 2016-04-15 2021-10-29 Cancer Research Tech Ltd Heterociklična jedinjenja kao inhibitori ret kinaze
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
CN110267960B (zh) 2017-01-18 2022-04-26 阿雷生物药品公司 作为RET激酶抑制剂的取代的吡唑并[1,5-a]吡嗪化合物
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
GB201705971D0 (en) 2017-04-13 2017-05-31 Cancer Res Tech Ltd Inhibitor compounds
TWI812649B (zh) 2017-10-10 2023-08-21 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
JOP20180094A1 (ar) 2017-10-18 2019-04-18 Hk Inno N Corp مركب حلقي غير متجانس كمثبط بروتين كيناز
WO2019143994A1 (en) 2018-01-18 2019-07-25 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
TW201938169A (zh) 2018-01-18 2019-10-01 美商亞雷生物製藥股份有限公司 作為RET激酶抑制劑之經取代吡唑并[3,4-d]嘧啶化合物
CN111971286B (zh) 2018-01-18 2023-04-14 阿雷生物药品公司 作为RET激酶抑制剂的取代的吡咯并[2,3-d]嘧啶化合物
JP7422084B2 (ja) 2018-04-03 2024-01-25 ブループリント メディシンズ コーポレイション Ｒｅｔ変化を有する癌の処置において使用するためのｒｅｔ阻害剤
MX2020009234A (es) 2018-04-05 2020-10-12 Merck Patent Gmbh Compuestos de heteroarilo como inhibidores de cinasas asociadas con receptores de interleucina-1 (irak) tipo ii y usos de los mismos.
ES2922314T3 (es) 2018-09-10 2022-09-13 Array Biopharma Inc Compuestos heterocíclicos condensados como inhibidores de cinasa RET
TWI833819B (zh) 2018-10-05 2024-03-01 美商安尼波那生物公司 用於治療與apj受體活性相關的病狀的化合物及組成物
KR102195348B1 (ko) 2018-11-15 2020-12-24 에이치케이이노엔 주식회사 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물
US12297197B2 (en) * 2019-04-03 2025-05-13 Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. Baiyunshan Pharmaceutical General Factory Pyrazolopyridine compound as RET inhibitor and application thereof
KR20220042293A (ko) * 2019-08-05 2022-04-05 베이징 즈지엔진루이 셩우이야오 커지 요우시엔공스 질소 함유 다환 축합 고리계 화합물, 이의 약학 조성물, 제조 방법 및 용도
CN115210226B (zh) * 2020-02-20 2024-01-09 广州白云山医药集团股份有限公司白云山制药总厂 喹啉类化合物
PH12022552987A1 (en) * 2020-05-07 2024-02-26 Adorx Therapeutics Ltd Antagonists of the adenosine a2a receptor
CA3183728A1 (en) 2020-05-29 2021-12-02 Blueprint Medicines Corporation Solid forms of pralsetinib
CN113214294A (zh) * 2020-06-10 2021-08-06 深圳铂立健医药有限公司 三环化合物、药物组合物及其应用
JP7588224B2 (ja) 2020-10-05 2024-11-21 エンライブン インコーポレイテッド Ｂｃｒ－ａｂｌチロシンキナーゼの阻害のための５－及び６－アザインドール化合物
WO2022140326A1 (en) * 2020-12-22 2022-06-30 Gilead Sciences, Inc. Substituted indole compounds
WO2022140325A1 (en) * 2020-12-22 2022-06-30 Gilead Sciences, Inc. 6-substituted indole compounds
TWI861488B (zh) 2021-04-16 2024-11-11 美商基利科學股份有限公司 噻吩并吡咯化合物
CN113248518B (zh) * 2021-06-21 2022-03-25 山东大学 嘧啶哌嗪类衍生物及其制备方法与应用
KR20240056747A (ko) 2021-09-10 2024-04-30 길리애드 사이언시즈, 인코포레이티드 티에노피롤 화합물
JP2024539641A (ja) 2021-10-15 2024-10-29 ステムライン セラピューティクス，インコーポレーテッド 癌の治療に使用するための変異ｒｅｔキナーゼの阻害剤
AU2024207083A1 (en) * 2023-01-09 2025-07-17 University Of Florida Research Foundation, Incorporated Pparg modulators
KR20250023311A (ko) * 2023-08-09 2025-02-18 주식회사 대웅제약 신규한 화합물, 및 이를 포함하는 암 또는 종양의 예방 또는 치료용 약학적 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010006086A2 (en) * 2008-07-08 2010-01-14 Intellikine, Inc. Kinase inhibitors and methods of use
WO2012148540A1 (en) * 2011-02-23 2012-11-01 Intellikine, Llc Combination of kanase inhibitors and uses threof

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0322779A3 (en) 1987-12-29 1991-05-08 Yoshitomi Pharmaceutical Industries, Ltd. Benzolactam compounds and pharmaceutical uses thereof
US5480883A (en) 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
AU779008C (en) * 1999-01-11 2005-06-30 Princeton University High affinity inhibitors for target validation and uses thereof
US7119200B2 (en) 2002-09-04 2006-10-10 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7429596B2 (en) 2003-06-20 2008-09-30 The Regents Of The University Of California 1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof
JP2008520744A (ja) 2004-11-19 2008-06-19 ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア 抗炎症性ピラゾロピリミジン
WO2006092430A1 (de) 2005-03-03 2006-09-08 Universität des Saarlandes Selektive hemmstoffe humaner corticoidsynthasen
CA2630271C (en) 2005-11-17 2014-04-08 Osi Pharmaceuticals, Inc. Fused bicyclic mtor inhibitors
AR057960A1 (es) 2005-12-02 2007-12-26 Osi Pharm Inc Inhibidores de proteina quinasa biciclicos
TW201307354A (zh) 2005-12-29 2013-02-16 Abbott Lab 蛋白質激酶抑制劑
GB0610242D0 (en) 2006-05-23 2006-07-05 Novartis Ag Organic compounds
JP2008063278A (ja) 2006-09-07 2008-03-21 Fujifilm Finechemicals Co Ltd １−ピリジン−４−イル−インドール類の製造方法
PT2201840E (pt) 2006-09-22 2012-02-14 Pharmacyclics Inc Inibidores da tirosina quinase de bruton
JP2010532756A (ja) * 2007-07-06 2010-10-14 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド ｍＴＯＲＣ１及びｍＴＯＲＣ２の両方の阻害剤を含む組み合わせ抗癌療法
DK2240451T3 (da) 2008-01-04 2017-11-20 Intellikine Llc Isoquinolinonderivater substitueret med en purin, der er anvendelig som pi3k-inhibitorer
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
US8637542B2 (en) * 2008-03-14 2014-01-28 Intellikine, Inc. Kinase inhibitors and methods of use
US20110224223A1 (en) 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
CA2738429C (en) 2008-09-26 2016-10-25 Intellikine, Inc. Heterocyclic kinase inhibitors
WO2010059593A1 (en) 2008-11-18 2010-05-27 Intellikine, Inc. Methods and compositions for treatment of ophthalmic conditions
KR101061599B1 (ko) 2008-12-05 2011-09-02 한국과학기술연구원 비정상 세포 성장 질환의 치료를 위한 단백질 키나아제 저해제인 신규 인다졸 유도체, 이의 약학적으로 허용가능한염 및 이를 유효성분으로 함유하는 약학적 조성물
AP2012006294A0 (en) 2009-11-05 2012-06-30 Rhizen Pharmaceuticals Sa Novel kinase modulators.
US9765037B2 (en) 2010-01-28 2017-09-19 University Of Washington Through Its Center For Commercialization Compositions and methods for treating toxoplasmosis, cryptosporidiosis, and other apicomplexan protozoan related diseases
WO2011094628A1 (en) 2010-01-28 2011-08-04 University Of Washington Compositions and methods for treating toxoplasmosis. cryptosporidiosis and other apicomplexan protozoan related diseases
UY33288A (es) * 2010-03-25 2011-10-31 Glaxosmithkline Llc Derivados de indolina inhibidores de la proteina quinasa r del reticulo endoplasmatico
WO2011153553A2 (en) 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
US20130296316A1 (en) 2010-07-09 2013-11-07 Michael P. Pollastri Antiparasitic Agents Based On mTOR Inhibitors
WO2012151562A1 (en) 2011-05-04 2012-11-08 Intellikine, Llc Combination pharmaceutical compositions and uses thereof
HK1198579A1 (en) 2011-08-10 2015-04-30 Novartis Pharma Ag Jak p13k/mtor combination therapy
JP6342805B2 (ja) * 2011-09-02 2018-06-13 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 置換ピラゾロ［３，４−ｄ］ピリミジンおよびその用途
US20140377285A1 (en) 2011-11-08 2014-12-25 Intellikine, Llc Treatment regimens using multiple pharmaceutical agents
CA2856803A1 (en) 2011-11-23 2013-05-30 Intellikine, Llc Enhanced treatment regimens using mtor inhibitors
US8501724B1 (en) 2012-01-31 2013-08-06 Pharmacyclics, Inc. Purinone compounds as kinase inhibitors
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
US9738610B2 (en) 2012-09-24 2017-08-22 Whitehead Institute For Biomedical Research Indazole derivatives and uses thereof
GB201217285D0 (en) 2012-09-27 2012-11-14 Univ Central Lancashire Indole derivatives
CN105246482A (zh) 2013-03-15 2016-01-13 因特利凯有限责任公司 激酶抑制剂的组合及其用途
JP6360881B2 (ja) 2013-03-22 2018-07-18 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 触媒的ｍｔｏｒｃ１／２阻害薬及びオーロラａキナーゼの選択的阻害薬の組合せ
CA2922058A1 (en) 2013-10-18 2015-04-23 Medivation Technologies, Inc. Heterocyclic compounds and methods of use
CA2922044A1 (en) 2013-10-18 2015-05-14 Medivation Technologies, Inc. Pyrazolo-, imidazolo- and pyrrolo-pyridine or -pyrimidine derivatives as inhibitors o brutons kinase (btk)
GB201321146D0 (en) 2013-11-29 2014-01-15 Cancer Rec Tech Ltd Quinazoline compounds
CA2967125C (en) 2014-11-14 2022-10-25 Nerviano Medical Sciences S.R.L. 6-amino-7-bicyclo-7-deaza-purine derivatives as protein kinase inhibitors
EP3250290A4 (en) 2015-01-26 2018-07-11 University of Washington Compositions and methods for treating toxoplasmosis, cryptosporidiosis and other apicomplexan protozoan related diseases
EP3334430B1 (en) 2015-08-13 2025-02-26 San Diego State University Research Foundation Atropisomerism for increased kinase inhibitor selectivity
HK1258779A1 (zh) * 2015-09-16 2019-11-22 Loxo Oncology Inc. 用於治療癌症的作為btk抑制劑的吡唑並嘧啶衍生物
WO2017160717A2 (en) 2016-03-15 2017-09-21 Memorial Sloan Kettering Cancer Center Method of treating diseases using kinase modulators
RS62322B1 (sr) * 2016-04-15 2021-10-29 Cancer Research Tech Ltd Heterociklična jedinjenja kao inhibitori ret kinaze
PT3442535T (pt) 2016-04-15 2022-09-05 Cancer Research Tech Ltd Compostos heterocíclicos como inibidores da ret quinase

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010006086A2 (en) * 2008-07-08 2010-01-14 Intellikine, Inc. Kinase inhibitors and methods of use
WO2012148540A1 (en) * 2011-02-23 2012-11-01 Intellikine, Llc Combination of kanase inhibitors and uses threof

Also Published As

Publication number Publication date
SI3442980T1 (sl) 2021-11-30
KR20220054894A (ko) 2022-05-03
IL262185B (en) 2022-02-01
CN115650985B (zh) 2024-08-02
BR112018071097B1 (pt) 2024-02-20
RU2742115C2 (ru) 2021-02-02
EP3442980A1 (en) 2019-02-20
KR20180134983A (ko) 2018-12-19
IL289793B2 (en) 2023-03-01
CN115650985A (zh) 2023-01-31
IL289793A (en) 2022-03-01
IL262185A (en) 2018-11-29
AU2020220079B2 (en) 2022-04-21
US20230339954A1 (en) 2023-10-26
CA3020778A1 (en) 2017-10-19
HRP20211362T1 (hr) 2021-11-26
EP3442980B1 (en) 2021-06-09
JP2021193108A (ja) 2021-12-23
ES2886587T3 (es) 2021-12-20
SG11201808878UA (en) 2018-11-29
AU2017250448B2 (en) 2020-05-21
EP3960180A1 (en) 2022-03-02
CN109195972A (zh) 2019-01-11
PL3442980T3 (pl) 2021-12-06
WO2017178844A1 (en) 2017-10-19
KR102706837B1 (ko) 2024-09-19
BR122023026297A2 (pt) 2024-01-16
RU2018138471A3 (OSRAM) 2020-05-15
SG10201911665UA (en) 2020-01-30
RU2018138471A (ru) 2020-05-15
BR112018071097A2 (pt) 2019-01-29
IL289793B (en) 2022-11-01
SMT202100538T1 (it) 2021-11-12
JP2023159230A (ja) 2023-10-31
AU2017250448A1 (en) 2018-11-01
JP2019515903A (ja) 2019-06-13
US20210155628A1 (en) 2021-05-27
KR20240142568A (ko) 2024-09-30
US20250236624A1 (en) 2025-07-24
HUE056135T2 (hu) 2022-01-28
CN109195972B (zh) 2022-10-28
RS62322B1 (sr) 2021-10-29
AU2020220079A1 (en) 2020-09-03
AU2022203916A1 (en) 2022-06-23
US11548896B2 (en) 2023-01-10
NZ747678A (en) 2024-05-31
MX2021013110A (es) 2021-11-17
DK3442980T3 (da) 2021-08-30
IL297192A (en) 2022-12-01
JP6943876B2 (ja) 2021-10-06
US10954241B2 (en) 2021-03-23
LT3442980T (lt) 2021-09-27
MX387394B (es) 2025-03-18
PT3442980T (pt) 2021-09-13
US20190106425A1 (en) 2019-04-11
CY1124478T1 (el) 2022-07-22
KR102390578B1 (ko) 2022-04-26
MX2018012609A (es) 2019-08-01

Similar Documents

Publication Publication Date Title
AU2020220079B2 (en) Heterocyclic compounds as RET kinase inhibitors
US11661423B2 (en) Heterocyclic compounds as RET kinase inhibitors
AU2022202325B2 (en) Compounds useful as RET inhibitors
HK40071396A (en) Heterocyclic compounds as ret kinase inhibitors
HK40085278A (en) Heterocyclic compounds as ret kinase inhibitors
HK1260208B (en) Heterocyclic compounds as ret kinase inhibitors
NZ787350A (en) Heterocyclic compounds as ret kinase inhibitors
NZ786565A (en) Heterocyclic compounds as ret kinase inhibitors
HK1260373A1 (en) Heterocyclic compounds as ret kinase inhibitors
HK1260373B (en) Heterocyclic compounds as ret kinase inhibitors

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 10 SEP 2020

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT FILED 10 SEP 2020